TG Therapeutics Inc. (TGTX) gave investors something to smile about Tuesday evening, releasing preliminary fourth-quarter revenue numbers that show its flagship drug Briumvi is gaining serious traction.
The biotech company expects Briumvi to generate approximately $182 million in U.S. net product revenue for Q4 2025, capping off a full-year haul of about $594 million domestically. Add in international sales, and total global revenue for 2025 comes in around $616 million.
But the real story here is the 2026 outlook. TG Therapeutics is targeting total global revenue between $875 million and $900 million next year, with U.S. Briumvi sales alone expected to hit $825 million to $850 million. That's a hefty jump from 2025 levels and signals management's confidence that the drug's momentum isn't slowing down.
"Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for Briumvi. With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow," said CEO Michael Weiss.
Investors responded enthusiastically, pushing shares up 6.60% to $29.71 in after-hours trading.
